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Decorin and biglycan, the two best studied members of the small leucine-rich
proteoglycan (SLRP) family, have been implicated in regulating cancer growth
and inflammation, respectively. Decorin expression is almost always sup-
pressed by cancer cells but abundantly produced by activated stromal fibro-
blasts in the tumor microenvironment [1]. Often an inverse relationship exists
between cancer growth and decorin expression, suggesting that decorin is an
‘endogenous guardian’ from the matrix. The mechanism of decorin-evoked
tumor repression is linked to its ability to potently induce the endogenous
synthesisofp21, a key inhibitorofcyclin-dependentkinases. This is carried out
by soluble decorin binding in a paracrine fashion to several receptor tyrosine
kinases (RTKs) including the EGFR, IGF-IR and Met (see Figure 1) [2].
Thus, decorin is a natural RTK inhibitor and systemic delivery of recombinant
decorin inhibits the growth of various tumor xenografts [3,4]. Currently, it is a
matter of debate of how decorin exactly inactivates specific receptors, given the
fact that RTKs are ubiquitously expressed. One explanation involves a
hierarchical mode of receptor affinity insofar as dissociation constants range
from 1 nM in the case of Met [5] to 90 nM for EGFR. Thus, it could be
envisioned that decorin, by acting as a pan-RTK inhibitor, would target many
different types of tumors that exhibit differential RTK binding affinities for
decorin. In most cases analyzed thus far, decorin evokes a rapid and protracted
internalization of both EGFR and Met via caveolar-mediated endocytosis, a
process that often leads to silencing of the receptors. Indeed, decorin blocks
several biological processes associated with Met activation, such as cell scatter,
evasion and migration [5]. One of the cellular mechanisms affected by this
matrix molecule is via downregulation of the non-canonical b-catenin pathway.
This leads to suppression of Myc, a downstream target of b-catenin, culminat-
ing in Myc proteasomal degradation [6]. Since Myc is a ‘master regulator’ which
can affect up to 1500 genes, it is not surprising to predict that novel functional
roles for decorin will be discovered in the near future.
The other SLRP structurally related to decorin, that is, biglycan, acts as a
danger signal and triggers both innate and adaptive immune responses. Under
physiological conditions, the ubiquitously expressed biglycan is sequestered in
the extracellular matrix and is immunologically inert. Upon tissue stress or
injury, resident cells secrete proteolytic enzymes, which degrade the extra-
cellular matrix and thus liberate biglycan and fragments thereof. Soluble
biglycan and some of its fragments interact with Toll-like receptor (TLR)-2
and TLR4. By activating TLRs, biglycan triggers the synthesis of various
proinflammatory cytokines (e.g. TNFa and IL-1b) and chemoattractants,
thereby recruiting macrophages into damaged areas in order to resolve the
injury (see Figure 1) [7]. Thus, soluble biglycan acts as a danger signal, which
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Multiple signaling pathways evoked by decorin and biglycan regulating
cancer growth and inflammation. For details see text.initiates a rapid innate immune response without the need
for de novo synthesis of ‘warning’ molecules. In addition,
upon stimulation with proinflammatory cytokines, resident
cells and infiltrating macrophages synthesize full-length
biglycan leading to the recruitment of additional macro-
phages, which are also capable of synthesizing and secreting
biglycan [7]. This creates a feed-forward loop that leads to
robust proinflammatory signaling. Moreover, biglycan is
capable of clustering TLR2/4 with purinergic P2X7 recep-
tors, thereby autonomously activating the NLRP3 inflam-
masome and caspase-1 and secretion of mature IL-1b (see
Figure 1) [8].
Besides recruiting macrophages, biglycan stimulates the
TLR2/4-dependent synthesis of key chemoattractants for
T and B lymphocytes and is thus also involved in the
adaptive immune response (see Figure 1). Biglycan specifi-
cally recruits B1 lymphocytes which are responsible for T
cell-independent production ofantibodies.This represents
an early defense against pathogens, before the adaptive
immune response is activated. The biological importance
of these mechanisms has been shown in systemic lupus
erythematosus (SLE), a prototypic autoimmune disease
affecting mainly young women. In SLE, soluble biglycan
stimulates the synthesis of autoantibodies and enhances
recruitmentofmacrophages aswell asTandB lymphocytes
resulting in enhanced inflammation in target organs. Nota-
bly, biglycan attracts B cells to chronically inflamed non-
lymphoid organs and promotes the development of tertiary
lymphoid tissue and acceleration of disease [9].
Collectively, these findings shed new light on the mech-
anisms of sterile inflammation, which plays a key role in
tissue repair and regeneration (e.g., wound healing),
ischemia/reperfusion injury (e.g., myocardial infarction)
and autoimmune diseases (e.g., rheumatoid arthritis,
SLE) among others. There is emerging evidence that
soluble biglycan is generated in non-pathogen-mediatedwww.sciencedirect.com inflammatory diseases and autonomously triggers sterile
inflammation by orchestrating TLR2/4 and NLRP3
inflammasome signaling [9]. On the other hand, in
pathogen-mediated inflammation, the affinity of biglycan
to receptors sensing either gram-positive or gram-nega-
tive pathogens allows for enhancement of inflammation
via a second TLR, which is not involved in pathogen
sensing [10].
The SLRPs are emerging as powerful signaling molecules
affecting both cancer growth and inflammation. Thus,
because cancer and inflammation are closely linked, we
envisage that SLRPs such as decorin and biglycan could
potentially become valid natural therapeutic agents or
target themselves. A novel emerging concept is that, upon
release from the extracellular matrix, a ‘basically inert’
matrix component can turn into either a tumor repressor
or a pro-inflammatory danger signal, which can sub-
sequently drive innate and adaptive immune responses.
This concept will offer novel perspectives in designing
new pharmacological agents for therapeutic interventions
in cancer, inflammatory and autoimmune diseases.
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